Stebbins J W, Jaffe H, Möller J R
Demyelinating Disorders Unit, LMCN, NINDS, NIH, Bethesda, MD 20892, USA.
Neurochem Res. 1998 Jul;23(7):1005-10. doi: 10.1023/a:1021092624046.
Purified human central nervous system myelin contains an endogenous cysteine protease which degrades the 100-kDa myelin-associated glycoprotein into a slightly smaller 90-kDa derivative called dMAG, and which has been implicated in demyelinating diseases. The native proteolytic site in human MAG was determined in order to characterize this cysteine protease in humans further. This was accomplished by identifying the carboxy-terminus of purified dMAG. The results of these experiments, in conjunction with peptidolysis assays of myelin, demonstrated that the enzyme which proteolyses MAG is extracellular and has cathepsin L-like specificity. Furthermore, it was shown that this cathepsin L-like activity potentially was regulated by the endogenous extracellular inhibitor cystatin C.
纯化的人中枢神经系统髓磷脂含有一种内源性半胱氨酸蛋白酶,该酶可将100 kDa的髓磷脂相关糖蛋白降解为略小的90 kDa衍生物,称为dMAG,并且该酶与脱髓鞘疾病有关。确定了人MAG中的天然蛋白水解位点,以便进一步表征人类中的这种半胱氨酸蛋白酶。这是通过鉴定纯化的dMAG的羧基末端来完成的。这些实验的结果,结合髓磷脂的肽水解分析,表明水解MAG的酶位于细胞外,具有组织蛋白酶L样的特异性。此外,研究表明,这种组织蛋白酶L样活性可能受内源性细胞外抑制剂胱抑素C的调节。